Status:
COMPLETED
Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)
Lead Sponsor:
Allergan
Conditions:
Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
Stage 1 is a patient-masked, dose-escalation, safety evaluation of brimonidine intravitreal implant. Patients will receive implant in one eye and "sham" treatment (meaning no treatment) in the fellow ...
Eligibility Criteria
Inclusion
- Geographic atrophy in both eyes due to age-related macular degeneration
- Visual acuity between 20/40 to 20/320
Exclusion
- Known allergy to brimonidine
- Uncontrolled systemic disease or infection of the eye
- Recent eye surgery or injections in the eye
- Female patients who are pregnant, nursing or planning a pregnancy
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 8 2011
Estimated Enrollment :
119 Patients enrolled
Trial Details
Trial ID
NCT00658619
Start Date
May 1 2008
End Date
April 8 2011
Last Update
August 21 2018
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Abilene, Texas, United States
2
Sydney, New South Wales, Australia
3
Karlsruhe, Germany
4
Udine, Italy